Quarterly Result14 May 2026, 08:11 pm
Alivus Life Sciences FY26 Revenue Up 6.9% YoY to ₹25,518 Mn
AI Summary
Alivus Life Sciences Ltd (formerly Glenmark Life Sciences) reported a 6.9% YoY increase in revenue for FY26, reaching ₹25,518 Mn. EBITDA grew by 19.6% YoY to ₹8,577 Mn, with margins at 33.6%. PAT stood at ₹5,645 Mn, up 16.2% YoY. Q4FY26 revenue grew by 6.1% YoY to ₹6,891 Mn, with EBITDA at ₹2,373 Mn, up 13.8% YoY. The company generated a strong free cash flow of ₹2,590 Mn, with cash and equivalents at ₹7,824 Mn as of March 31, 2026. The CDMO business saw an 18% YoY growth in the second half of the year.
Key Highlights
- FY26 Revenue from operations grew 6.9% YoY to ₹25,518 Mn.
- FY26 EBITDA increased by 19.6% YoY to ₹8,577 Mn, with margins at 33.6%.
- FY26 PAT grew 16.2% YoY to ₹5,645 Mn, with margins at 22.1%.
- Q4FY26 Revenue from operations grew 6.1% YoY to ₹6,891 Mn.
- Company reports strong free cash flow of ₹2,590 Mn for FY26.